Sean Mcgarry

Array ( [id] => 5465844 [patent_doc_number] => 20090326044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-31 [patent_title] => 'RNAi-Mediated Inhibition of Ocular Targets' [patent_app_type] => utility [patent_app_number] => 12/536698 [patent_app_country] => US [patent_app_date] => 2009-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19148 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0326/20090326044.pdf [firstpage_image] =>[orig_patent_app_number] => 12536698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6627326 [patent_doc_number] => 20100004141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-07 [patent_title] => 'siRNA targeting polo-like Kinase-1 (PLK-1)' [patent_app_type] => utility [patent_app_number] => 12/460876 [patent_app_country] => US [patent_app_date] => 2009-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 35053 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0004/20100004141.pdf [firstpage_image] =>[orig_patent_app_number] => 12460876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5398474 [patent_doc_number] => 20090318537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-24 [patent_title] => 'SILENCING OF TGF BETA TYPE II RECEPTOR EXPRESSION BY SIRNA' [patent_app_type] => utility [patent_app_number] => 12/505911 [patent_app_country] => US [patent_app_date] => 2009-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12611 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0318/20090318537.pdf [firstpage_image] =>[orig_patent_app_number] => 12505911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6187701 [patent_doc_number] => 20110171176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-14 [patent_title] => 'COMPLEMENT ANTAGONISTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/003062 [patent_app_country] => US [patent_app_date] => 2009-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28220 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20110171176.pdf [firstpage_image] =>[orig_patent_app_number] => 13003062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6006703 [patent_doc_number] => 20110119781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-19 [patent_title] => 'Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes' [patent_app_type] => utility [patent_app_number] => 13/054111 [patent_app_country] => US [patent_app_date] => 2009-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 18730 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0119/20110119781.pdf [firstpage_image] =>[orig_patent_app_number] => 13054111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5490426 [patent_doc_number] => 20090291497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-26 [patent_title] => 'siRNA targeting transducin (beta)-like 3 (TBL3)' [patent_app_type] => utility [patent_app_number] => 12/459489 [patent_app_country] => US [patent_app_date] => 2009-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 34535 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20090291497.pdf [firstpage_image] =>[orig_patent_app_number] => 12459489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7574159 [patent_doc_number] => 20110269815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-03 [patent_title] => 'METHODS OF REDUCING CELLULAR PROLIFERATION BY INHIBITING ACSVL3' [patent_app_type] => utility [patent_app_number] => 13/001066 [patent_app_country] => US [patent_app_date] => 2009-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12453 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0269/20110269815.pdf [firstpage_image] =>[orig_patent_app_number] => 13001066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6016952 [patent_doc_number] => 20110224281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-15 [patent_title] => 'RNA ANTAGONISTS TARGETING HSP70-2' [patent_app_type] => utility [patent_app_number] => 12/999597 [patent_app_country] => US [patent_app_date] => 2009-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17583 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0224/20110224281.pdf [firstpage_image] =>[orig_patent_app_number] => 12999597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6389880 [patent_doc_number] => 20100317839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'TP EXPRESSION-INHIBITING COMPOUND AND SIRNA SEQUENCE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/484858 [patent_app_country] => US [patent_app_date] => 2009-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 1868 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0317/20100317839.pdf [firstpage_image] =>[orig_patent_app_number] => 12484858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9440911 [patent_doc_number] => 08710021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-29 [patent_title] => 'Inhibition of HRP-3 using modified oligonucleotides' [patent_app_type] => utility [patent_app_number] => 12/997720 [patent_app_country] => US [patent_app_date] => 2009-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 6564 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12997720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5552301 [patent_doc_number] => 20090286287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-19 [patent_title] => 'METHODS AND COMPOSITIONS FOR USE IN PREPARRING siRNAs' [patent_app_type] => utility [patent_app_number] => 12/477835 [patent_app_country] => US [patent_app_date] => 2009-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17120 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0286/20090286287.pdf [firstpage_image] =>[orig_patent_app_number] => 12477835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6113912 [patent_doc_number] => 20110190374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'METHODS OF TREATING A MEIOTIC KINESIN ASSOCIATED DISEASE' [patent_app_type] => utility [patent_app_number] => 12/994920 [patent_app_country] => US [patent_app_date] => 2009-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11906 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0190/20110190374.pdf [firstpage_image] =>[orig_patent_app_number] => 12994920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7808205 [patent_doc_number] => 20120059159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-08 [patent_title] => 'DIFFERENTIATION THERAPY FOR SARCOMAS' [patent_app_type] => utility [patent_app_number] => 13/320418 [patent_app_country] => US [patent_app_date] => 2009-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10580 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0059/20120059159.pdf [firstpage_image] =>[orig_patent_app_number] => 13320418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5386535 [patent_doc_number] => 20090227780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-09-10 [patent_title] => 'siRNA targeting connexin 43' [patent_app_type] => utility [patent_app_number] => 12/454271 [patent_app_country] => US [patent_app_date] => 2009-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 34711 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0227/20090227780.pdf [firstpage_image] =>[orig_patent_app_number] => 12454271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5485875 [patent_doc_number] => 20090275640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-05 [patent_title] => 'siRNA targeting inner centromere protein antigens (INCENP)' [patent_app_type] => utility [patent_app_number] => 12/454055 [patent_app_country] => US [patent_app_date] => 2009-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 34427 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20090275640.pdf [firstpage_image] =>[orig_patent_app_number] => 12454055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5937706 [patent_doc_number] => 20110213010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-01 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON\'S DISEASE' [patent_app_type] => utility [patent_app_number] => 12/991883 [patent_app_country] => US [patent_app_date] => 2009-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20761 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20110213010.pdf [firstpage_image] =>[orig_patent_app_number] => 12991883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6178145 [patent_doc_number] => 20110178158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'Set of Antiangiogenic Molecules and Use Thereof' [patent_app_type] => utility [patent_app_number] => 12/991200 [patent_app_country] => US [patent_app_date] => 2009-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3348 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178158.pdf [firstpage_image] =>[orig_patent_app_number] => 12991200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5480939 [patent_doc_number] => 20090203896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-13 [patent_title] => 'MODULATION OF SURVIVIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 12/430465 [patent_app_country] => US [patent_app_date] => 2009-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38437 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0203/20090203896.pdf [firstpage_image] =>[orig_patent_app_number] => 12430465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102707 [patent_doc_number] => 20110166200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'METHODS OF USING MIR210 AS A BIOMARKER FOR HYPOXIA AND AS A THERAPEUTIC AGENT FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 12/989198 [patent_app_country] => US [patent_app_date] => 2009-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 36166 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20110166200.pdf [firstpage_image] =>[orig_patent_app_number] => 12989198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6016950 [patent_doc_number] => 20110224280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-15 [patent_title] => 'Pharmaceutical Composition Comprising Anti PCSK9 Oligomers' [patent_app_type] => utility [patent_app_number] => 12/988289 [patent_app_country] => US [patent_app_date] => 2009-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14375 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0224/20110224280.pdf [firstpage_image] =>[orig_patent_app_number] => 12988289 [rel_patent_id] =>[rel_patent_doc_number] =>)